Pharmacokinetics and ADME characterizations of antibody-drug conjugates

DOI: 10.1007/978-1-62703-541-5_7
Methods in Molecular Biology, 2013, 1045, 117-31.

#	Paper	IF	Citations
17	Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. *Drug Metabolism and Disposition*, **2014**, 42, 1914-20	4	63
16	Antibody-drug conjugates: an emerging modality for the treatment of cancer. *Annals of the New York Academy of Sciences*, **2014**, 1321, 41-54	6.5	62
15	Intracellular Catabolism of an Antibody Drug Conjugate with a Noncleavable Linker. *Drug Metabolism and Disposition*, **2015**, 43, 1341-4	4	22
14	Calculated conjugated payload from immunoassay and LC-MS intact protein analysis measurements of antibody-drug conjugate. *Bioanalysis*, **2016**, 8, 2205-2217	2.1	18
13	Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. *Cancer Research*, **2016**, 76, 2710-9	10.1	140
12	Antibody-drug conjugates as drug carrier systems for bioactive agents. *International Journal of Polymeric Materials and Polymeric Biomaterials*, **2016**, 65, 1-10	3	8
11	Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. *Cancer Science*, **2017**, 108, 1458-1468	6.9	30
10	From R&D to Clinical Supplies. *Organic Process Research and Development*, **2017**, 21, 590-600	3.9	5
9	Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics. *AAPS Journal*, **2017**, 19, 130-140	3.7	10
8	Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned. *Clinical Pharmacokinetics*, **2018**, 57, 687-703	6.2	45
7	High throughput screening against pantothenate synthetase identifies amide inhibitors against and. *In Silico Pharmacology*, **2018**, 6, 9	4.3	3
6	Long-term delivery of protein and peptide therapeutics for cancer therapies. *Expert Opinion on Drug Delivery*, **2019**, 16, 1113-1131	8	5
5	Pharmacokinetics of protein and peptide conjugates. *Drug Metabolism and Pharmacokinetics*, **2019**, 34, 42-54	2.2	15
4	Antibody-drug conjugates: smart weapons against cancer. *Archives of Medical Science*, **2020**, 16, 1257-1262	2.9	2
3	ADME of Biologicals and New Therapeutic Modalities. **2021**,		
2	Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.. *Pharmacology & Therapeutics*, **2022**, 236, 108106	13.9	3
1	Nano-bio interactions: A major principle in the dynamic biological processes of nano-assemblies.. *Advanced Drug Delivery Reviews*, **2022**, 186, 114318	18.5	0